These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 30304737

  • 1. Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration.
    Sitnilska V, Altay L, Enders P, Hermann M, Muether PS, Fauser S.
    Ophthalmologica; 2019; 241(3):154-160. PubMed ID: 30304737
    [Abstract] [Full Text] [Related]

  • 2. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
    Enders P, Sitnilska V, Altay L, Fauser S.
    Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
    [Abstract] [Full Text] [Related]

  • 3. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH, Sun HJ, Lee SJ.
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [Abstract] [Full Text] [Related]

  • 4. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration.
    Kim M, Kim ES, Seo KH, Yu SY, Kwak HW.
    Indian J Ophthalmol; 2016 Jun; 64(6):427-33. PubMed ID: 27488150
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K, Hong T, Nair R, Chow NCC, Broadhead GK, Wijeyakumar W, Chang AA.
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [Abstract] [Full Text] [Related]

  • 6. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R, Reiter GS, Mittermüller TJ, Schranz M, Reumueller A, Schlanitz FG, Weigert G, Pollreisz A, Sacu S, Schmidt-Erfurth U.
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The factors associated with retinal pigment epithelium tear development in the early phase after treatment initiation for age-related macular degeneration.
    Shiose S, Notomi S, Hashimoto S, Nagata J, Fukuda Y, Kano K, Ishikawa K, Sonoda KH.
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3171-3180. PubMed ID: 38713397
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration.
    Lee B, Yoo G, Yun C, Oh J.
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2163-2172. PubMed ID: 31367847
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M, Giustolisi R, Marchiori J, Bruscolini A, Mallone F, Fameli V, Nebbioso M, Abdolrahimzadeh S.
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [Abstract] [Full Text] [Related]

  • 12. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Cho HJ, Park SM, Kim J, Nah SK, Lee J, Lee DW, Kim JW.
    Acta Ophthalmol; 2021 Jun; 99(4):e540-e546. PubMed ID: 32996674
    [Abstract] [Full Text] [Related]

  • 13. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    Lanzetta P, Cruess AF, Cohen SY, Slakter JS, Katz T, Sowade O, Zeitz O, Ahlers C, Mitchell P.
    Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
    [Abstract] [Full Text] [Related]

  • 14. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM, Dos Reis Veloso CE, Dorairaj S, Nehemy MB.
    Ophthalmic Res; 2017 Dec; 58(1):18-26. PubMed ID: 28301850
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Invernizzi A, Nguyen V, Arnold J, Young S, Barthelmes D, Gillies MC.
    Ophthalmology; 2018 Feb; 125(2):237-244. PubMed ID: 28993010
    [Abstract] [Full Text] [Related]

  • 17. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, Gune S, Balasubramanian S.
    Ophthalmology; 2020 Oct; 127(10):1360-1370. PubMed ID: 32402555
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINAL ANGIOMATOUS PROLIFERATION.
    Hata M, Yamashiro K, Oishi A, Ooto S, Tamura H, Miyata M, Ueda-Arakawa N, Kuroda Y, Takahashi A, Tsujikawa A, Yoshimura N.
    Retina; 2017 Nov; 37(11):2069-2077. PubMed ID: 28085772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.